BMY : Analysis & Opinions

  1. Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day

    December 18, 2014
    Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day
  2. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  3. Is It A Breakout? See The Point-And-Figure Chart

    November 18, 2014
    These stocks have broken out of a triple top formation using point-and-figure charting, a bullish sign.
  4. These Astute Bets Helped Hedge Funds Win Big

    May 13, 2014
    Some astute bets helped hedge fund managers increase their average take by 50% in 2013, though the majority of funds were ...
  5. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  6. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  7. Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry.

    A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  8. It's No Accident That Drugs Are Expensive

    August 30, 2013
    Branded drugs are expensive in large part because it's expensive and risky to develop them
  9. Vertex Building A Fortress In Cystic Fibrosis

    August 28, 2013
    Vertex is in the early days of what could be a $10B franchise in cystic fibrosis treatment.
  10. AstraZeneca Goes Back To The M&A Well Yet Again

    August 26, 2013
    AstraZeneca's acquisition of Amplimmune could pay big dividends in a decade.
  11. Amgen Sweetens The Bid And Secures Onyx

    August 26, 2013
    Amgen finalizes a value-additive deal for Onyx
  12. Will Immunotherapy Disrupt The Oncology Market?

    August 20, 2013
    Immunotherapy could radically change the treatment of cancer, and the revenue opportunities for pharmaceutical companies.
  13. Better Margins Can't Hide Merck's Growth Challenges

    July 30, 2013
    Merck's near-term growth is looking weak, but margin improvements and an underestimated pipeline could offer upside.
  14. 8 Stages Of New Drug Development

    July 29, 2013
    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these ...
  15. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  16. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  17. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  18. Warning: The Rebound May Be Over For Big Pharma

    June 10, 2013
    As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of ...
  19. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  20. After A Big Rally, Pfizer Might Need Some Rest

    May 21, 2013
    A big rally has brought Pfizer back to fair value.
  21. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  22. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane ...
  23. Pipeline Setback for Idenix - Analyst Blog

    February 7, 2013
    Idenix Pharmaceuticals, Inc. (IDIX) recently announced that the company has decided to discontinue its clinical development ...
  24. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  25. Why Smart Investors Are Pouring Trillions into This Type Of Stock

    January 18, 2013
    For decades, analysts have heralded small-cap stocks as the real growers in the stock market. And they're right to some extent; ...
  26. Abbott Labs Spins Off AbbVie: Which Is The Better Buy?

    January 4, 2013
    January 2 was the first day of trading for the pharmaceutical spin-off.
  27. The Absolute Highest Yields You'll Find... in 8 Major Sectors

    December 13, 2012
    Readers of my articles should know by now that I'm always on the lookout for good dividend-paying ideas. There's no better ...
  28. BMY/ABT Present Oncology Data - Analyst Blog

    December 12, 2012
    Bristol-Myers Squibb Company (BMY) and partner Abbott Laboratories (ABT) recently presented data on their oncology candidate ...
  29. Gilead Plans to Split Stock 2-for-1 - Analyst Blog

    December 11, 2012
    Recently, the board of directors at Gilead Sciences Inc. (GILD) authorized a two-for-one stock split. The action, which will ...
  30. LIFE Continues Acquisition Spree - Analyst Blog

    October 9, 2012
    Life Technologies (LIFE) is on an acquisition bandwagon, targeted towards building its diagnostics franchise. The company ...
  31. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally. ...
  32. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  33. Bristol-Myers Squibb's Second Quarter Earnings Report

    July 25, 2012
    Bristol-Myers Squibb Company (NYSE:BMY) announced its results for the second quarter on July 25, 2012. Bristol-Myers Squibb ...
  34. Setback for Chelsea Therapeutics - Analyst Blog

    July 6, 2012
    Chelsea Therapeutics International, Ltd. (CHTP) recently suffered a setback when the US Food and Drug Administration (FDA), ...
  35. Biggest Healthcare Sector Movers for July 3, 2012

    July 3, 2012
    The market is doing well so far today. The Nasdaq has moved up 0.7%; the S&P 500 is up 0.7%; and the Dow has risen 0.6%. ...
  36. Update on Amylin's Metreleptin - Analyst Blog

    June 19, 2012
    Amylin Pharmaceuticals, Inc. (AMLN) recently provided an update on its regulatory status for metreleptin. In an 8K filing ...
  37. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  38. 15 Biotech Companies Waiting For FDA Approval

    March 21, 2012
    Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the ...
  39. Pfizer Shrugs Off the Loss Of Lipitor

    February 6, 2012
    Pfizer remains very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit ...
  40. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  41. Four Stocks Flashing Buy Signals

    January 24, 2012
    Here are four of the most attractive stocks based on fundamentals and the charts.
  42. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  43. Healthcare Stocks On The Move

    December 13, 2011
    These four healthcare stocks are showing above-average performance.
  44. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  45. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  46. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors. ...
  47. Top Dividend Stocks Owned By The Pros

    August 2, 2011
    Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
  48. A Trio of Solid Defensive Stocks

    July 27, 2011
    There’s been a continual shift to defensive, income-oriented shares since the second quarter, and these three top the list, ...
  49. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  50. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  51. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  52. 4 Stocks Hitting Highs During The Pullback

    May 6, 2011
    Four stocks that are holding up well during a short-term market pullback.
  53. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  54. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  55. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  56. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  57. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  58. Great Dividend Yield Payouts

    August 26, 2010
    In good times more risk can be taken. But for now, let's look at a couple of companies paying shareholders a healthy dividend. ...
  59. Roll With Your Spinoff

    August 17, 2010
    If you own a stock that's contemplating a spinoff, consider the possibility that the new entity rather than the parent is ...
  60. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  61. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma. ...
  62. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount. ...
  63. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  64. The Motorola Breakup

    February 16, 2010
    Motorola finally announced its long-awaited breakup, but shareholders shouldn't get their hopes up just yet.
  65. IPO Market Slows Down With Market Correction

    February 10, 2010
    The initial public offering market has recently hit a few bumps, as investors become nervous about the overall stock market. ...
  66. The Best IPOs Of 2009

    December 16, 2009
    Chinese companies stole the show in the initial public offering market in 2009, making some lucky (or smart) investors very ...
  67. Four Healthcare Stocks On Fire

    November 18, 2009
    Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...
  68. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others. ...
  69. 5 Stocks With Low P/Es And High Dividends

    June 19, 2009
    Finding undervalued gems can help boost porfolio returns. Check out five potential diamonds in the rough.
  70. Companies That Are Beating Earnings Estimates

    April 2, 2009
    Companies that have exceeded earnings estimates are worthy of further research as analysts' ratings might boost stock prices. ...
  71. Bristol-Myers Pays Healthy Dividends

    February 12, 2009
    Bristol-Myers is among five companies with a great forward annual dividend yield.
  72. Is Stock Market Capitulation Over?

    October 15, 2008
    We examine the present market for clues to where and when we'll see a bottom.
  73. A Billion Isn't What It Used To Be

    October 10, 2008
    It might be a lot of money to the average person, but $1 billion is small change on Wall Street. We look at a few things ...
  74. What Imclone Means To Eli Lilly

    October 7, 2008
    Eli Lilly expands its cancer offering with the acquisition of Imclone. Can the union boost Eli Lilly's floundering stock ...
  75. Duke Energy Is High Yield Royalty

    March 4, 2008
    Duke Energy's very healthy dividend yield makes it a solid investment as a fixed-income proxy, especially during a flight ...
  76. Johnson & Johnson Blows Away Q1 (JNJ)

    April 20, 2007
    J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
  77. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  78. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider. ...
  79. Consolidation Looks To Be In The Cards (MRK, BMY, SGP)

    September 18, 2006
    A look into the merger possiblities of three of the drug industry's major players.
Trading Center